… editorial initiative of Clinical and Experimental Rheumatology focusing on the relevant
novelties on rheumatic diseases published in the last year (1–11). In this review, particular focus …

… 2019 EULAR Recommendations (1), that specific treatment strategies have to be carefully
evaluated at single-patient level, bearing in mind the role of relevant comorbidities, potential …

… ≥1 CV risk factor treated with tofacitinib (5mg and 10mg twice daily) had increased chances
of developing VTE, compared to TNFis-treated … research informing the 2019 update of the …

… review, the authors aim to give their specific point of view on the most relevant and potentially
impacting novelties … antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 79; 685-99. …

… In light of the new research novelties, both … review we reported a Medline search of articles
in English published in the PubMed database from 1st January 2019 to 31st December 2019…

… In contrast to 2019, the 2022 EULAR recommendations compared bDMARD and csDMARD
… Graphical synthesis of novelties into management of rheumatoid arthritis (RA). The …

… This review highlights current challenges associated with the treatment of RA using small
molecule inhibitors … Peficitinib was approved for the management of RA in Japan in 2019 [50]. …

Rheumatoid arthritis (RA) is a multifactorial autoimmune … mechanism, good RA management
requires a multidisciplinary … years due to medical advances in diagnosis and treatment, that …

… SILVAGNI E, LUCIANO N, SCIRÈ CA: One year in review 2018: novelties in the treatment of
… in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. …

… Reporting Items for Systematic Reviews and Meta-Analysis … Reviews to ensure transparency,
reliability, and novelty. … assessment tool (RoB−2 2019), we categorized the included …